Embecta (NASDAQ:EMBC) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Embecta (NASDAQ:EMBC) announced its quarterly earnings results on Thursday. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.20, Zacks reports. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. Embecta updated its FY 2025 guidance to 2.700-2.900 EPS.

Embecta Stock Performance

Shares of Embecta stock traded down $0.71 during midday trading on Thursday, hitting $17.50. The company had a trading volume of 225,546 shares, compared to its average volume of 363,636. The company has a 50 day moving average of $19.70 and a 200 day moving average of $16.52. The stock has a market capitalization of $1.02 billion, a P/E ratio of 12.96, a P/E/G ratio of 0.97 and a beta of 1.20. Embecta has a 52-week low of $9.93 and a 52-week high of $21.48.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th were given a $0.15 dividend. The ex-dividend date of this dividend was Friday, December 6th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.43%. Embecta’s dividend payout ratio is currently 44.44%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. BTIG Research raised Embecta from a “neutral” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Wednesday, November 27th. Morgan Stanley raised Embecta from an “underweight” rating to an “equal weight” rating and raised their price objective for the company from $13.00 to $20.00 in a research report on Monday, December 2nd.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.